Daniele Galanti

Dr. Daniele Galanti

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in Clinical Breast Cancer
Verified
Journal Article
Closed access
SGStefania Gori
Stefania Gori
Fabio PuglisiFabio Puglisi
Fabio Puglisi
SMStefano Moroso
Stefano Moroso
AFAlessandra Fabi
Alessandra Fabi
NVNicla La Verde
Nicla La Verde
AIAlessandro Inno
Alessandro Inno

10 November 2022 in Tumori Journal
Verified
Journal Article
Closed access
MVMaria La Vecchia
Maria La Vecchia
IFIvan Fazio
Ivan Fazio
NBNicolò Borsellino
Nicolò Borsellino
ACAntonio Lo Casto
Antonio Lo Casto
DGDaniele Galanti
Daniele Galanti
Introduction: This monocentric, single-arm, retrospective study investigated the role of stereotactic body radiotherapy in patients with metastatic castration resistant prostate cancer who experienced oligoprogression during androgen receptor targeted agents. Methods: We retrospectively enrolled metastatic castration resistant prostate cancer patients treated with androgen receptor targeted agents between December 2016 and January 2022. All patients experienced an oligoprogression (defined as the appearance and/or the progression of ⩽5 bone or nodal or soft tissue metastases) during treatment with androgen receptor targeted agents and received stereotactic body radiotherapy upon oligoprogressive sites, preserving the androgen receptor targeted agents. Further stereotactic body radiotherapy upon new metastatic sites was permitted. Patients showing visceral metastases or receiving palliative radiotherapy were excluded. Progressive disease at >5 metastatic sites or the appearance of visceral metastases led to a change of the systemic treatment. Primary endpoints were 36-month survival rate and 36-month rate of patients receiving treatment with androgen receptor targeted agents. Secondary endpoints were local disease control, biochemical response and safety. Results: We analyzed data from 30 patients. The 36-month survival rate was 90% (27 patients); 36-month rate of patients who were still on treatment with androgen receptor targeted agents was 50%. 20 of 30 patients had performed imaging control after a single course of stereotactic body radiotherapy: overall response rate was 50%, while clinical benefit was 93%. No ⩾G2 adverse events related to stereotactic body radiotherapy were recorded. Conclusions: Stereotactic body radiotherapy in oligoprogressive metastatic sites during androgen receptor targeted agent treatment resulted in a feasible and effective treatment to delay the start of next-line systemic treatment and prolong overall survival in metastatic castration resistant prostate cancer. Longer follow-up and further prospective studies are necessary to confirm our preliminary results.

29 March 2022 in Case Reports in Oncology
Verified
Journal Article
Open access
PDF file
MVMaria La Vecchia
Maria La Vecchia
DGDaniele Galanti
Daniele Galanti
IFIvan Fazio
Ivan Fazio
RPRosario Paratore
Rosario Paratore
NBNicolò Borsellino
Nicolò Borsellino
Prostate cancer is the most frequent malignant tumor in male. Despite its incidence increased in the last few years, the mortality is gradually decreasing, even in patients with metastatic prostate cancer (mPC). Unfortunately, prolongation of survival leads to the exhaustion of therapeutic chances. Therefore, patients with good performance status (PS) may remain out of further active treatments. We report the clinical case of a 71-year-old patient with symptomatic metastatic castration-resistant prostate cancer (mCRPC) and good PS who progressed after multiple treatments and started a hormonal therapy with megestrol acetate (MA). MA is a synthetic progestin used for treatment of mPC in 1990s since it was shown to have an antiandrogen activity. In our case, MA managed to overcome resistance to androgen receptor-targeted agents (ARTAs), getting a dramatic biochemical and radiological response and a rapid improvement of symptoms. Our clinical case shows that MA is an interesting therapeutic option especially in long-survivor patients with mCRPC and a long progression-free survival during ARTAs therapies.

2 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
AVAntonello Veccia
Antonello Veccia
DED’Argento Ettore
D’Argento Ettore
FMFloriana Morgillo
Floriana Morgillo
EPElio Gregory Pizzutilo
Elio Gregory Pizzutilo
FVFabiana Vitiello
Fabiana Vitiello
AIAlessandro Inno
Alessandro Inno
Background: Chemoimmunotherapy combinations represent the standard first-line treatment for non-oncogene addicted metastatic NSCLC (mNSCLC). However, evidence in elderly patients remains limited and conflicting. We conducted an analysis of the efficacy and safety of chemoimmunotherapy in patients aged ≥75 years enrolled in the Real-Combo Lung study, an observational study including patients with non-oncogene-addicted mNSCLC and PD-L1 expression < 50%. Patients and Methods: The primary objective of the study was to compare progression-free survival (PFS) and overall survival (OS) between patients aged ≥75 (elderly cohort) and those aged <75 years (non-elderly cohort). Safety outcomes were evaluated as a secondary objective. Results: A total of 495 patients were enrolled, with 89 (18%) aged ≥75 and 406 (82%) aged <75 years. No significant differences in PFS and OS were observed between the two cohorts. The median PFS was 13.3 months (95% CI: 9.3–NR) in the elderly cohort and 10.5 months (95% CI: 9.5–12.9) in the non-elderly cohort (unadjusted HR 0.84, 95% CI: 0.61–1.16, p = 0.29). The median OS was 17.5 months (95% CI: 14.7–NR) versus 21.4 months (95% CI: 17–NR), respectively (unadjusted HR 1.09, 95% CI: 0.76–1.56, p = 0.63). In multivariable analysis, ECOG PS ≥ 2 and baseline use of steroids were significantly associated with a worse outcome in the elderly cohort for both PFS and OS. Safety data did not differ significantly between cohorts. Conclusions: In this real-world study, elderly patients with mNSCLC derived outcomes comparable to those of younger patients, with similar efficacy and a manageable safety profile when treated with chemoimmunotherapy combinations.

10 June 2026 in Clinical and Translational Imaging
Verified
Journal Article
Closed access
PDF file
Riccardo LaudicellaRiccardo Laudicella
Riccardo Laudicella
DGDaniele Galanti
Daniele Galanti
Pierpaolo AlongiPierpaolo Alongi
Pierpaolo Alongi
DADemetrio Aricò
Demetrio Aricò
LCLuigi Castorina
Luigi Castorina
NBNicolò Borsellino
Nicolò Borsellino